Skip to main
MRNA
MRNA logo

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 7%
Hold 53%
Sell 27%
Strong Sell 0%

Bulls say

Moderna's positive outlook is driven by its strategic goal of achieving $1.4 to $1.7 billion in cost reductions by 2027, demonstrating a commitment to operational efficiency. Additionally, the company aims to break even by 2028, implying a focus on financial sustainability and potential profitability in the near future. Furthermore, Moderna's ongoing development of 35 mRNA candidates across diverse therapeutic areas highlights its innovative pipeline and capacity for growth, particularly in preventative vaccines.

Bears say

The excerpts highlight that Moderna is currently experiencing significant challenges in the short term related to its respiratory syncytial virus (RSV) and COVID vaccine sales, which may negatively impact its revenue forecasts. Despite having a diverse pipeline with 35 mRNA candidates targeting various therapeutic areas, these material headwinds may hinder immediate financial performance and investor confidence. While there are potential upside risks through increased vaccine revenue, cost management, or mergers and acquisitions, the prevailing conditions suggest a cautious outlook for the company's stock.

Moderna (MRNA) has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 7% recommend Buy, 53% suggest Holding, 27% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 15 analysts, Moderna (MRNA) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.